|
News For BMY;PFE;DUF;CG;HLF;CALM From The Last 14 Days Check below for free stories on BMY;PFE;DUF;CG;HLF;CALM the last two weeks. |
|
|
| May 23, 2013 |
| 06:02 EDT |  | BMY | Bristol-Myers implied volatility at upper end of index mean range
|
|
| 05:47 EDT | | BMY | Stocks with implied volatility movement; SKS BMY
Stocks with implied volatility movement; Saks (SKS), Bristol-Myers (BMY) according to IVolatility. |
|
| May 22, 2013 |
| 16:00 EDT | | BMY | Options Update; May 22, 2013
 Subscribe for More Information |
|
| 10:33 EDT |  | BMY | Bristol-Myers jumps after Citi ups rating on cancer potential
Subscribe for More Information |
|
| 10:16 EDT |  | BMY | Bristol-Myers spikes higher following upgrade, levels to watch
Subscribe for More Information |
|
| 10:00 EDT |  | BMY | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 08:59 EDT | | PFE | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 08:06 EDT | | PFE | Zoetis comments on Pfizer’s split-off plans for remaining interest
Subscribe for More Information |
|
| 08:04 EDT | | PFE | Pfizer announces plan to split-off remainder of Zoetis
Subscribe for More Information |
|
| 08:02 EDT | | PFE | Pfizer announces plan to split-off remainder of Zoetis
Subscribe for More Information |
| |
| 06:31 EDT |  | HLF | Icahn up $228M, Ackman down $10M on Herbalife, NY Post reports
Carl Icahn's long position in Herbalife (HLF) is up $228M while Bill Ackman's short position in the company is down $10M, New York Post reports. Reference Link |
|
| 06:05 EDT | | BMY | Bristol-Myers upgraded to Buy from Neutral at Citigroup
Subscribe for More Information |
|
| May 21, 2013 |
| 12:16 EDT | | HLF | Herbalife resumes, up 3.5% to $50.95 after naming PwC as auditor
Subscribe for More Information |
|
| 12:13 EDT | | HLF | Herbalife selects PricewaterhouseCoopers as auditor, PwC to re-audit prior years
Herbalife announced that the Audit Committee of its Board of Directors has engaged PricewaterhouseCoopers as the company's independent auditors. PwC will commence work immediately to re-audit the company's consolidated financial statements for the fiscal years ended December 31, 2010, 2011 and 2012 and PwC will also review the company’s condensed consolidated financial statements for the first quarter of 2013. “We are very pleased to have engaged PwC to serve as the Company’s independent auditor. They will begin work immediately to re-audit the Company’s December 31, 2010, 2011 and 2012 consolidated financial statements. Investors should rest assured that the Company will be working to assist PwC in any way necessary to facilitate their work,” said the chairman of Herbalife’s audit committee Leroy Barnes. |
|
| 12:07 EDT | | HLF | Herbalife engages PricewaterhouseCoopers as new audit firm
Subscribe for More Information |
|
| 11:56 EDT | | HLF | Herbalife trading halted, pending news
Subscribe for More Information |
|
| 10:06 EDT | | HLF | Herbalife May weekly volatility spikes on sharp rally
Subscribe for More Information |
|
| 07:34 EDT |  | BMY | UBS to host a conference
Subscribe for More Information |
|
| 07:24 EDT | | BMY | Global Health Care to host a conference
Subscribe for More Information |
|
| 07:16 EDT | | PFE | Pfizer management to meet with Leerink
Subscribe for More Information |
| |
| May 20, 2013 |
| 17:04 EDT | | PFE | Pfizer discontinues phase 3 study of inotuzumab ozogamicin
Subscribe for More Information |
|
| 10:36 EDT | | HLF | Herbalife June volatility low as shares at four-month high
Herbalife May weekly call option implied volatility is at 60, June is at 44, August and November is at 43; compared to its 26-week average of 58 according to Track Data, suggesting decreasing outer month price movement. |
|
| 10:03 EDT | | BMY | Shire advances after report renews takeover speculation
Subscribe for More Information |
|
| 07:50 EDT | | CG | Gulf wealth funds raise private equity investments, Reuters reports
Sovereign wealth funds in the Gulf Arab region are increasing their allocations to private equity investments at a faster rate than other types of investment, U.S. fund manager Invesco said in a new study, reports Reuters. Large sovereign funds have been looking for alternative investments to give better returns than low-yielding staples such as U.S. Treasuries.Reference Link |
|
| 06:30 EDT |  | BMY | Leerink estimates Shire takeout value at least $110 per share
Leerink says a takeover price for Shire (SHPG) would need to be at least $110 per share in order to get the company's board to consider a sale. The firm notes a Daily Mail report last night said Bristol-Myers (BMY) has engaged advisors to study an acquisition of Shire and that Shire's CEO has contacted bankers to consider anti-takeover measures. Leerink believes a Bristol-Myers takeover of Shire would make sense and keeps an Outperform rating on Shire. |
|
| 06:25 EDT | | BMY | Shire may return cash to thwart takeover, Daily Mail reports
Subscribe for More Information |
|
| May 17, 2013 |
| 13:21 EDT | | BMY | Options with increasing implied volatility: CPRT BMY GDI HNZ
Subscribe for More Information |
|
| May 16, 2013 |
| 16:32 EDT | | BMY | Bristol-Myers announces intention to voluntarily delist preferred stock
Subscribe for More Information |
|
| 13:20 EDT | | BMY | Follow-up: Bristol-Myers upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Bristol-Myers citing the company's multi-billion dollar immuno-oncology prospects. The firm says there were additional responses reported in the press briefing with combination nivolumab and Yervoy. Leerink has a $51 price target for shares. |
|
| 13:14 EDT | | BMY | Bristol-Myers upgraded to Outperform from Market Perform at Leerink
Subscribe for More Information |
| |
| 08:55 EDT | | PFE, BMY | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
|
| 08:38 EDT | | BMY | Bristol-Myers shares likely to give back recent gains, says Leerink
Leerink expects shares of Bristol-Myers to give back recent gains after ASCO published abstracts last night. The firm found the abstracts as in-line with, but not above, its expectations for nivolumab alone or immuno-oncology combination therapy and keeps a Market Perform rating on Bristol-Myers. |
|
| 05:52 EDT | | BMY | Stocks with implied volatility movement; BMY SLV
Subscribe for More Information |
|
| May 15, 2013 |
| 17:26 EDT | | HLF | Third Point gives quarterly update on stakes
NEW STAKES: Virgin Media (VMED), Tiffany (TIF), B/E Aerospace (BEAV), Anadarko (APC), and Thermo Fisher (TMO). INCREASED STAKES: International Paper (IP), Abbvie (ABBV), TransDigm (TDG), Constellation Brands (STZ), and Dollar General (DG). DECREASED STAKES: Delphi (DLPH), Murphy Oil (MUR), AIG (AIG), LyondellBasell (LYB), and Liberty Global (LBTYA). LIQUIDATED STAKES: Tesoro (TSO), Morgan Stanley (MS), Symantec (SYMC), Herbalife (HLF), and Illumina (ILMN). |
|
| 16:48 EDT | | HLF | Icahn gives quarterly update on stakes
Subscribe for More Information |
|
| 11:28 EDT | | BMY | Options with increasing implied volatility: BMY AGNC EBIX IAU
Subscribe for More Information |
|
| 09:43 EDT | | BMY | Active equity option families trading on open
Subscribe for More Information |
|
| 07:11 EDT | | CG | Some buyout firms move beyond buyouts, WSJ reports
Subscribe for More Information |
|
| 06:08 EDT | | CG | On the Fly: Periodicals Wrap-Up
Subscribe for More Information |
|
| May 14, 2013 |
| 07:24 EDT | | BMY | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. |
| |
| May 13, 2013 |
| 10:09 EDT |  | CG | On The Fly: Analyst Downgrade Summary
Subscribe for More Information |
|
| 06:44 EDT | | CG | Carlyle Group downgraded to Neutral from Buy at UBS
Subscribe for More Information |
|
| May 10, 2013 |
| 16:29 EDT |  | PFE | On The Fly: Closing Wrap
Subscribe for More Information |
|
| 12:56 EDT | | HLF | Carl Icahn says shares of Herbalife should be selling a lot higher
|
|
| 12:31 EDT | | PFE | On The Fly: Midday Wrap
Subscribe for More Information |
|
| 11:48 EDT | | PFE, BMY | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information |
|
| 09:21 EDT | | PFE | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 08:08 EDT | | PFE | Pain Therapeutics discloses Pfizer reassessing continued Remoxy partnership
Pain Therapeutics (PTIE) disclosed a letter its CEO was sent from partner Pfizer (PFE) in which the drug maker said it is reassessing its endorsement of the Remoxy program "given the years of delay, additional cost incurred to bring the program to this point and development work left in the program." Pfizer said it will be reaching out to Pain Therapeutics "shortly" to have a confidential discussion about the terms of the companies' contractual agreement over the pain drug. Pfizer that it appears there is a regulatory pathway forward for Remoxy, but that the company does not expect to respond to submit a Complete Response letter for Remoxy to the FDA before mid-2015. Pfizer added in its letter to Pain Therapeutics "no final decision has been made at this time" on how it will proceed with the Remoxy development program. Shares of Pain Therapeutics fell 47% to $2.81 in pre-market trading following the disclosure of the correspondence. |
|
| 07:46 EDT | | PFE | DURECT says additional clinical studies needed for Remoxy
DURECT (DRRX) announced that Pfizer (PFE) has provided an update on Remoxy in a regulatory filing. Pfizer's disclosure included: "We have been working to address the issues raised in the letter, which primarily relate to manufacturing. We met with the FDA in March 2013 to discuss our plan to address the June 2011 "complete response" letter. We received written guidance from the FDA in May regarding required next steps, including additional clinical studies, to address the letter. Based on this guidance, we are considering our options with respect to Remoxy. If we elect to continue development of Remoxy, we would not expect to submit a response to the 'complete response' letter before mid-2015." DURECT said it understands from Pfizer that additional clinical studies are necessary and include, in part, a pivotal bioequivalence study with the modified formulation to bridge to the clinical data conducted with the original formulation, as well as an abuse potential study with the modified Remoxy formulation. Remoxy is based on DURECT's ORADUR technology. Shares of Pfizer's Remoxy partner Pain Therapeutics (PTIE) are down 56% in pre-market trading, while shares of DURECT are down 13%, or 20c, to $1.39. |
|
| 06:26 EDT | | HLF | Dan Loeb confirms out of Herbalife stake, NY Post reports
Subscribe for More Information |
| |
| 05:53 EDT | | CG | Carlyle Group bids on stake Rio Tinto Australian copper mine, Reuters reports
The Carlyle Group (CG) submitted a bid for Rio Tinto's (RIO) 80% stake in the Northparkes copper mine in Australia, sources say, reports Reuters. Analysts have suggested Rio Tinto could receive up to $1B for the mine. Reference Link |
|
|
|
|
|
